For HER2 positive GC, the single-arm HER-FLOT study investigated the combination of trastuzumab and FLOT as perioperative treatment for locally advanced GEJ adenocarcinoma.87 The primary endpoint of achieving a pathological response rate >20% was reached by the study. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.